BAL sample

Bronchoscopy Procedure

BAL Contamination Source Points to Patient Risk of SMA

A comprehensive investigation concluded that the SMA detected in samples resulted from incomplete cleaning and decontamination of the fiberoptic bronchoscope.

Bronchoalveolar lavage (BAL) is one of the most common procedures used to diagnose and treat lung infection. BAL samples, however, may be compromised by contaminated tools and accessories, delaying subsequent diagnosis and treatment.

Further investigation into the source of BAL fluid contamination can help prevent the spread of disease to patients and healthcare staff.

A study out of Wuhan City, China, found a contaminated fiberoptic bronchoscope contributed to nosocomial contamination of Stenotrophomonas maltophilia (SMA) of 25 BAL fluid samples in three months. On-site sampling revealed SMA to also be present in a cleaning tank and on the hands of healthcare personnel working with the contaminated scope.

The presence of SMA in the bronchoscope lumen also increased the risk of patient exposure to this antibiotic-resistant disease, according to the study authors, Bende Liu and Shenglan Tong.

“A comprehensive investigation concluded that the SMA detected in samples resulted from incomplete cleaning and decontamination of the fiberoptic bronchoscope,” Liu and Tong concluded. “Although patients did not exhibit symptoms of infection, the obvious safety risks triggered appropriate measures to prevent reoccurrence.”

SMA is an antimicrobial-resistant pathogen often found in respiratory and intestinal tracts. It commonly infects hospitalized patients with low immune function, according to the study.

After researchers detected SMA in BAL samples, they sought to find the cause of the contamination and best treatment options to prevent patient infection.

The BAL samples were taken from May to August 2018. Once SMA contamination was found in 25 samples, sterile cotton swabs were used to take samples from the fiberoptic bronchoscope, cleaning brush, and hands of cleaning personnel.

The bronchoscope was determined to be the source of the contamination. That was based on the drug-resistant profiles of the contaminants in the BAL fluid and inner channels of the scope. The study authors speculated contamination resulted from inadequate cleaning and sterilization. If biofilm formed on the inner channels of the scope, that could hinder future decontamination efforts, they wrote.

To mitigate further risk, the hospital staff removed the contaminated bronchoscope from use. Reprocessing personnel received additional training in bronchoscope cleaning and decontamination.

No patients in the study exhibited any symptoms related to SMA infection. “An investigation of Stenotrophomonas maltophilia-positive culture caused by fiberoptic bronchoscope contamination” was published in BMC Infectious Diseases in December 2019.

For more information:

Single-use bronchoscopes eliminate the need for reprocessing and help prevent patient cross-contamination. In tandem with a single-use bronchoscope, Ambu offers a closed loop sampling system that helps reduce cross contamination in BAL. For more information about the aScope BronchoSampler, click here

More Infection Prevention Articles
Why Medical Technologists Should be Considered for IP Roles
Prevention Strategies
The COVID-19 pandemic has exacerbated the healthcare worker shortage and infection preventionists are no exception.
What Does ANSI/AAMI ST91 Mean for Endoscope Reprocessing in Your Department?
Prevention Strategies
The new updates classify high-risk endoscopes while enhancing all areas of their reprocessing.
More From Single-Use Endoscopy
Study: Visual Inspection Found Damage and Debris in All Reprocessed Scopes Tested

Prevention Challenges

Borescopes and additional magnification revealed damage and residue or debris on all the fully reprocessed endoscopes examined in a recent study.

What is the ‘Holiday Effect’ on ERCPs?

Gastrointestinal Endoscopy Procedure

Researchers have found certain post-ERCP complications to be more frequent in December. But why?

Medicare penalties for high readmissions are lower than they have been, but still affect nearly 2,300 U.S. hospitals.

Value-Based Care

Lowering readmission rates remains a national priority for payers, providers and policymakers seeking to improve healthcare while reducing costs.